The Reverse Total Hip — Promise, Perils, and the Data That Will Decide

By Tiger

We've all heard the drumbeat: total hip arthroplasty (THA) is a mature, commodity market. Implants are reliable, survival curves flatline nicely out to 15–20 years for well-positioned constructs, and the big players battle over razor-thin margins on polyethylene, ceramics, and fixation tweaks.

I have written about how the smart innovation money has pivoted to the Throughput Accelerator Strategy — robotics, navigation, outpatient pathways, bundled payments, and reducing the total cost of care. The real moat, we were told, moved from the metal to the ecosystem.

But every so often, pure implant architecture reasserts itself and forces the question: Can structural engineering still create a durable clinical (and commercial) moat? Florida-based Hip Innovation Technology (HIT) and its Reverse Hip Replacement System (Reverse HRS) are the latest test case. With a multi-center FDA Investigational Device Exemption (IDE) pivotal trial (NCT05357378) actively enrolling at high-volume sites including Tampa General Hospital and Florida Orthopaedic Institute, the orthopedic world is watching closely.

Reversing the Biomechanical Equation

Let's be precise. This is not a reverse shoulder. No deltoid takeover, no rotator-cuff bypass. HIT is flipping the articulating surfaces while preserving the native center of rotation.

Conventional THA
Acetabular cup → highly cross-linked polyethylene (XLPE) liner → cobalt-chromium (or ceramic) femoral head → femoral stem.HIT Reverse HRS
Acetabular cup → fixed cobalt-chromium ball (locked on a trunnion inside the cup) → XLPE liner housed inside a femoral cup → femoral stem.The ball now lives on the acetabular side; the liner lives on the femoral side. The design maintains constant contact across a wider arc, dramatically increases the effective jump distance (the distance the femoral component must travel before the head can lever out over the rim), and keeps load vectors more perpendicular to the liner throughout the flexion-extension arc.

Bench and cadaver testing reportedly showed stability even with extreme acetabular malposition (up to 70° abduction or 40° anteversion) — no impingement, no dislocation in the tested extremes. The company claims the geometry uncouples component position from stability and wear, making the implant more forgiving of the positioning realities every surgeon faces.

The Spinopelvic Holy Grail

This is where the story gets compelling. Patients with lumbar stiffness, degenerative disc disease, or prior spinal fusion are the THA surgeon's nightmare. When a normal pelvis tilts posteriorly in sitting, it opens the acetabulum for safe flexion. In a fused or stiff spine, that compensatory rotation disappears. The cup stays put, leading to early impingement, edge-loading, and dislocation rates that can be 80% higher in the first six months post-THA compared with normal spines.Dual-mobility cups help but don't eliminate the underlying mechanical conflict. The Reverse HRS offers intrinsic geometric stability — a wider safe range of motion before impingement becomes possible. The FDA granted Compassionate Use approval specifically for stiff-spine and spinal-fusion patients while the broader IDE plays out.

If the design delivers, this isn't just a niche fix for complex revisions or high-risk primaries — it could redefine the "standard" primary for a growing demographic.The Evidence Base: From Bench to Five-Year RSAHIT didn't skip steps. Pre-clinical work included rigorous bench testing (consistent wear regardless of cup position, no runaway edge loading) and cadaver ROM/stability studies.The landmark data comes from Dr. Thomas Turgeon's Canadian single-center cohort using radiostereometric analysis (RSA) — the gold standard for detecting microscopic migration predictive of long-term loosening.

Key RSA findings (updated to 5 years):

- Femoral subsidence: consistently below 0.06 mm (well under the 1.5 mm safety threshold).
- Acetabular subsidence: below 0.09 mm (under the 1.0 mm threshold).
- Polyethylene linear wear: minimal, reaching only 0.19 ± 0.16 mm at five years — at or near the detection limit for much of the period.
- Significant improvements in patient-reported outcome measures (PROMs) for pain and function. prnewswire.com

These numbers predict exceptionally stable biologic fixation and low risk of aseptic loosening out to (and likely well beyond) 10 years. Early 2-year data from the same cohort already showed migration essentially at the RSA detection limit.

A 2024 case series by Lombardi et al. and early compassionate-use experiences add clinical color, with surgeons reporting no dislocations in their initial Reverse HRS cases and strong bony ingrowth on imaging.

Promise: A More Forgiving Implant in an Era of Perfect Positioning



In a world obsessed with robotics and AI planning to achieve “perfect” cup position every time, HIT asks a contrarian question: What if we just built a more forgiving implant?Potential upsides if the IDE data holds:

- Dramatically lower dislocation risk, especially in spinopelvic mismatch patients.
- Reduced need for extreme positioning precision or adjuncts like dual mobility in routine cases.
- Possibly lower wear-related osteolysis long-term due to uniform loading.

- A true premium-tier primary implant argument in a market that had largely abandoned hardware differentiation.
- Surgical workflow advantages (potentially fewer restrictions, less DME).

Market research commissioned by HIT suggested surgeons viewed it as a significant or revolutionary step forward, with substantial hypothetical market share.

Potential Dangers and Unanswered Questions

Innovation always carries risk. A scoping review published in 2026 (Khalifa) examined the early published evidence (one biomechanical study + three small clinical reports totaling ~24 patients, max 24-month follow-up) and raised important cautions.

Documented or theoretical concerns include:

- Novel design risks: Two tapers (acetabular ball trunnion + femoral cup-stem interface) theoretically double the opportunity for taper corrosion, fretting, or adverse local tissue reaction (ALTR) — though no such issues appeared in the short-term data.
- Early complication profile: In the small published series, overall complication rate reached ~29% (mostly transient or manageable: calcar crack, neuropraxia, IT band syndrome, one traumatic dislocation reduced closed, and one deep PJI requiring staged revision). While many were not device-specific, the rate is higher than typical modern primary THA series and warrants scrutiny in larger cohorts.
- Limited target-population data: Most early patients were standard osteoarthritis cases, not the high spinopelvic-risk patients the design is intended to help. Long-term performance in fused spines remains unproven.
- Learning curve and surgical complexity: Assembling the femoral cup + liner intraoperatively, ensuring secure locking of the acetabular ball, and managing a new set of instruments could introduce technique-specific issues not present with conventional systems.
- Long-term unknowns: Five-year RSA and wear data are excellent but still early for a novel bearing configuration. Wear debris behavior, backside wear on the femoral liner, and performance beyond 10 years are uncharted.
- Regulatory and adoption hurdles: Full FDA clearance hinges on the IDE results. Even with positive data, convincing payers and surgeons to adopt a premium-priced novel implant in a cost-sensitive environment will take time and compelling health-economic data.

- Conflict-of-interest lens: Much of the early data comes from investigators with manufacturer relationships; independent, large-scale confirmation is essential.

No technology is risk-free. The question is whether the stability gains outweigh any new failure modes.

Tigers Take

The Reverse HRS represents one of the most interesting pure hardware innovations in THA in over a decade. The biomechanical rationale is sound, the early RSA fixation and wear data are outstanding, and the spinopelvic application is genuinely unmet-need territory. If the ongoing IDE pivotal trial (head-to-head against legacy premium uncemented systems) reproduces the Canadian outcomes — particularly low dislocation rates and sustained PROM gains in both standard and complex patients — HIT will have something rare: a defensible clinical moat built on implant architecture rather than software or services.But the bar is high. Small early series show promise alongside a complication signal that needs larger-N clarification. Two tapers, a femoral cup construct, and a reversed bearing surface introduce variables that only time and volume will fully de-risk.We will be watching enrollment velocity, interim safety data, and — most importantly — the primary endpoint results of NCT05357378 with intense interest. If the numbers hold, this could be the implant that reminds the industry that biomechanics still matters and that not every moat has to be digital.

The data will decide. And in orthopedics, the data always has the final vote.OrthoStreams will continue tracking this closely.

Stay tuned for updates as IDE data matures.